Targeting KRAS in Pancreatic Cancer
Darren Cowzer, Mohammed Zameer, Michael Conroy, Walter Kölch, Austin G. Duffy
Abstract
Pancreatic cancer is mainly driven by mutations in the KRAS oncogene. While this cancer has shown remarkable therapy resistance, new approaches to inhibit mutated KRAS, KRAS activators and effectors show promise in breaking this therapeutic deadlock. Here, we review these innovations in therapies that target RAS signaling in pancreatic cancer from a clinical point of view. A number of promising approaches are currently in clinical trials or in clinical development. We focus on small-molecule drugs but also discuss immunotherapies and tumor vaccines.
Topics & Concepts
KRASPancreatic cancerMedicineClinical trialCancerCancer researchBioinformaticsOncologyColorectal cancerInternal medicineBiologyCancer Research and TreatmentsPancreatic and Hepatic Oncology ResearchUbiquitin and proteasome pathways